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Objectives: The safety and efﬁcacy of the RevoLix 2-m continuous wave laser for hysteroscopic myo-
mectomy (HM) was evaluated.
Materials and methods: A retrospective study was undertaken to evaluate 13 patients with symptomatic
submucous myomas, who were treated with HM using a RevoLix laser application. The evaluation items
included blood loss from surgery (estimated by the change between preoperative and postoperative
hemoglobin levels), surgical time, amount of distension media, specimen volume retrieved, complica-
tions, and success rate.
Results: The mean age of the patients was 38 years old; 10 patients were in the premenopausal status and
nine patients were nullipara. The surgical time was 91 minutes, and the distension media requirement
was 4500 mL. The postoperative hemoglobin level decreased to 1.2 g/dL compared with the preoperative
status. Mean specimen volume retrieved was 13.7 mm. No complications occurred. All patients reported
signiﬁcant improvement after HM during the 1-year follow-up.
Conclusion: The use of the Revolix laser for HM seemed to be safe and effective in the management of
symptomatic submucous myomas in this small population study.
Copyright  2013, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Hysteroscopic surgery has become the standard diagnostic and
therapeutic tool for intrauterine disease, including uterine cavity
anomalies, endometrial polyps, benign submucous ﬁbroids, and
even endometrial malignancies.1 Surgical procedures have
improved along with the advances in minimally invasive surgery
techniques,2e4 which are increasingly being used bymore surgeons
to treat malignant or benign tumors.5 Hysteroscopic procedures are
often considered minimally invasive, but complications occasion-
ally occur.6 Among these hysteroscopic procedures,7e12 hystero-
scopic myomectomy (HM) is one of the most advanced and is
associated with a signiﬁcantly higher rate of complications thanand Gynecology, Taipei Med-
, Number 252, Wusing Street,
ia-PaciﬁcAssociation forGynecologicEnother hysteroscopic procedures, particularly in complex cases.6
Complication rates have ranged from 0.3% to 28%, and ﬂuid over-
load and uterine perforation are the most frequent complications
during surgery.12 Other complications include bleeding, cervical
trauma, and air embolism; late complications include postoperative
intrauterine adhesion.13
The most dangerous complication during HM is an excessive
intravasation of the ﬂuid used to distend and irrigate the uterine
cavity, with resultant ﬂuid overload. Although management of this
risk relies on close monitoring of the ﬂuid balance and interruption
of the procedure prior to excessive ﬂuid absorption occurring,12,13
the use of electrolyte-free solution might be a critical factor.
However, standard electrosurgical operative hysteroscopy (such as
conventional monopolar resectoscope) mandates the use of an
electrolyte-free, low-viscosity solution (for example, 1.5% glycine,
3% D-sorbitol, 5% mannitol, and cystosol).9 These solutions, if
absorbed in excessive amounts, lead to ﬂuid-overload hypona-
tremia. Long-term morbidity and even death have been reported,
making prevention of this ﬂuid overload critical.13doscopyandMinimally InvasiveTherapy.PublishedbyElsevierTaiwanLLC.All rights reserved.
Table 1
Baseline characteristics of the enrolled women.
Age (y) 38.0  7.5
Body mass index (kg/m2) 19.1  2.3
Menstruation status
Premenopause 10
Postmenopause 3
Parity
Nulliparity 9
Multiparity 4
Data are presented as mean  standard deviation or case numbers.
Table 2
Baseline characteristics Surgical and postoperative parameters following hystero-
scopic myomectomy by RevoLix.
Surgical time (min) 91  32
Distension media volume used (mL) 4538  3039
Postoperative decreased hemoglobin level (g/dL) 1.21  0.59
Specimen volume retrieved 13.69  23.55 (mm3)
Complications 0 (0/13)
Distension media-related complications 0 (0/13)
Complicationsdpossibly related to thermal effect 0 (0/13)
Data are presented as mean  standard deviation or case numbers.
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introduced to the ﬁeld of hysteroscopic procedures. One of the
advances is the development of RevoLix (LISA Laser, Pleasanton,
CA, USA), a 2-m continuous wave diode-pumped solid-status
(DPSS) laser,14,15 which brings together all of the advantages of
existing laser principles in a single unit, and allows the surgeon to
perform the operative hysteroscopy in an isotonic environment.
This development may prevent the complications caused by
traditional electrolyte-free extension media. The aim of this study
was to evaluate the feasibility and the safety of this 2-m contin-
uous wave laser (RevoLix) using HM in the treatment of women
with symptomatic submucous myoma.
Materials and methods
Patients
Data from women with symptomatic submucous myomas
treated with HM between January 2005 and June 2005 were
evaluated. Inclusion criteria included: (1) age between 20 years and
55 years, (2) body mass index between 16 kg/m2 and 35 kg/m2, (3)
symptomatic submucous myoma, (4) a need for surgical treatment,
and (5) a strong desire expressed by the patient to preserve her
uterus. Exclusion criteria included: (1) a present or past history of
cancer, (2) an absence of pathology conﬁrmation, and (3) incom-
pletely recorded data.
Surgical procedures
The surgical procedure for HM using the RevoLix laser was as
follows. Under general anesthesia, the resectoscopic instrument
was introduced into the uterine cavity after the cervical canal had
been dilated with a number 10 Hegar dilator. A solution of 0.9%
saline was used as the distension media. The ﬁbroids were ﬁrst cut
into pieces until the residual ﬁbroids could be extracted by forceps
in both groups. After the ﬁbroids were removed, the resectoscope
was reintroduced for careful desiccation.
Evaluation parameters
The parameters for evaluation included surgical time (in mi-
nutes), postoperative hemoglobin change on the next day, disten-
sion media volume used, specimen volume retrieved, and
complications. Hyperglycemia was deﬁned as when the blood
sugar level was greater than 300 mg/dL during the perioperative
period.
Statistical analysis
SPSS (version 12.0; SPSS Inc., Chicago, IL, USA) statistical soft-
ware was used to analyze the patient data. Data were presented as
mean  standard deviation.
Results
A total of 13 patients were analyzed. Table 1 shows the general
characteristics of the enrolled patients who were treated with the
procedure. The mean surgical time was 91  32 minutes and
distension media volume requirement was 4538  3039 mL. The
mean hemoglobin level after surgery was 1.21  0.59 gm/dL lower
than the status prior to surgery. The average volume of retrieved
mass was 13.69  23.55 mm3. No distention media or thermal
effect-related complications occurred during the surgery (Table 2).
All patients were discharged uneventfully without postoperative
complications.Discussion
Approximately 20e40% of women of reproductive age have
uterine myomas,16e18 suggesting that these lesions are remarkably
common. Most uterine myomas are asymptomatic,19 although
some may cause symptoms that require deﬁnitive treatment.20,21
Hysterectomy has been considered a good choice if the woman
has completed child bearing.22 More recently, attention has been
paid to the development of pharmaceutical agents and less invasive
procedures or those performed by routes that incur less morbidity
than laparotomy.23 Frequently, such procedures are designed to
preserve the uterus. There aremany therapeutic strategies available
in themanagement of symptomatic uterinemyomas, but the choice
depends on the patient’s age, the reasons for treatment, the issue of
fertility preservation, and the patient’s preference.24 While the
uterus is not only a sexual organ but maintains important physio-
logical functions, to develop therapeutic approaches for the pres-
ervation of the uterus have become an important issue.16e18,20,24,25
Hysteroscopic surgery has seen signiﬁcant improvement in its
associated techniques and instruments, and has been developed
and used in the management of various intrauterine diseases.26,27
The application of resectoscopic surgery has been made possible
through the use of electrical current or lasers. The electrosurgical
system can be monopolar or bipolar. In the monopolar system, the
ﬂow of current from the extremity of the resectoscope (active
electrode) must reach the plate (passive electrode) in order to
complete the circuit. The use of monopolar electrodes requires the
use of nonconducting distending solution (sorbitol 5% or glycine
1.5%). Laser types include argon, krypton, neodymium-yttrium-
aluminum garnet (Nd:YAG), and diode lasers (e.g., RevoLix) and
all have been successfully used, but only the Nd:YAG laser has
found widespread application in hysteroscopic procedures.28,29
The RevoLix laser is a 2-m continuous wave laser excited by an
internal diode laser, and delivered by reusable and ﬂexible silica
ﬁbers.14,15 The RevoLix laser is reported to have the superior char-
acteristics of precise cutting and ablation, good hemostasis ability,
and direct vaporization without deep penetration, all of which are
attributed to its excellent water absorptive wavelength (2 m). This
property limits its laser effect to within 2 mm in front of the tip of
the ﬁber in an aqueous medium.14 When used in the management
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resection of hypertrophic prostate,14 the RevoLix laser has had good
results. Based on a similar concept, it may be possible to use the
RevoLix laser in the treatment of symptomatic submucous my-
omas. This study was conducted to assess the safety and efﬁcacy of
the RevoLix laser in the treatment of women with symptomatic
submucous myomas.
For submucous ﬁbroids, hysteroscopic resection (resectoscopy)
is an option for treatment because the tissue texture of the ﬁbroids,
unlike endometrial polyps, are ﬁrm and can seldom be removed
simply by dilatation and curettage. HM demonstrated less
morbidity, shorter hospital stays, shorter recovery time, and lower
costs than traditional laparotomy procedures.30 Consistent with
these results, we suggested that HM by RevoLix laser was a viable
choice for the treatment of women with symptomatic submucous
myomas.
However, many major complications, such as uterine mechani-
cal trauma, media-related complications, and unintended collateral
damage by electrosurgical instruments are associated with HM. In
the largest reported series, the complication rate of operative
hysteroscopy was 0.95%, and was directly related to the type of
procedure preformed.12 The key inducers for all these complica-
tions can be generalized into three factors: the force, themedia, and
the energy. We used electricity conventionally as the energy source
for cutting and coagulation (for example, monopolar electrodes). As
a result, the distension media are limited to electrolyte-free and
nonconductive ﬂuid (such as distilled water or sorbitol solutions).
These distension media are not physiologically isotonic, which
might induce a ﬂuid, electrolyte, and glucose imbalance during and
after the procedures. Water intoxication, hyponatremia, hypergly-
cemia, hematuria, and pulmonary edema are already well docu-
mented.13,31 To avoid these complications, the use of lasers as
replacement energy sources has been frequently studied. With the
introduction of laser instruments, physiologic saline solution can be
used as distension media and as a result, ﬂuid measurement might
become less complicated.
In addition to the media-related complications when using
monopolar electrodes, thermal injury is another potential compli-
cation and is worthy of our attention. The RevoLix laser exhibits
good water absorption, even 2.5 times stronger than the holmium-
YAG laser.14,15 This property brings the laser effect to tissue
restricted to less than 2 mm in front of the tip of the ﬁber in an
aqueous medium. The mechanism protects the tissue and organs
adjacent to the cut. A distance of 2 mm is a safe margin, because the
tissue further from 2 mm is unaffected by the RevoLix laser. A
precise and clear cut, good hemostasis, shallow penetration, and
direct vaporization can be achieved. Tissue damage is restricted to
less than 1 mm beneath the cut (data not shown). Objective
experience with its use yielded powerful cutting, vaporization, and
coagulation with greater safety. In addition, fewer bubbles and less
tissue debris formation allow the surgical ﬁeld much more visi-
bility. In this study, thermal injury was indeed absent when we
used the Revolix laser as a tool to complete HM.
Not every laser currently available is perfectly suitable for
endoscopic use because there are at least four minimum re-
quirements: (1) clear cutting ability, (2) good hemostasis effect, (3)
shallow penetration, and (4) delivery by ﬁbers. However, most la-
sers are more or less deﬁcient in some aspects. For example, the
carbon dioxide laser works with clear cutting and shallow pene-
tration, but it cannot be delivered with ﬁbers but with articulate
mirror arms. Another well-known laser system used in the hys-
teroscopic ﬁeld is the neodymium-YAG laser.28,29 Although the
neodymium-YAG laser exhibits good cutting and hemostasis
properties, its low water-absorptive wavelength results in the risk
of deep penetration. The holmium-YAG laser works only in a pulsedmode, which splatters tissue debris and disturbs the surgical pro-
cedure. In addition, the cutting edge of the holmium-YAG laser is
rough and causes more damage to the adjacent tissue. For these
reasons,, the RevoLix laser might be a better choice.
Bipolar electrode instruments mediated through a small caliber
hysteroscope without cervical dilatation and saline solution as a
distension medium were claimed to be superior.32,33 However,
because of their smaller size, these instruments seemed to be
preferable only for smaller and nonfundal polyps.34 Other in-
struments, such as the intrauterine morcellator required less sur-
gical time, however, the homeostatic imbalance during and after
the procedure might be a concern.35
The main disadvantage for the clinical application of RevoLix
laser might be the cost. Laser equipment currently tends to be
expensive, which signiﬁcantly reduces its widespread use.13 How-
ever, based on this study, although without well-designed control
group, the outcome demonstrated that the use of the RevoLix laser
for the treatment of womenwith symptomatic submucousmyomas
is reasonable and worthy of further study.
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